Member Info for martinu

Another view expressed is from warrants.

From Opti AGM yesterday :

"Resolution 5, a Special Resolution which sought to give the Directors power to issue new ordinary shares for cash other than to the Company's shareholders on a pro rata basis, was not passed."

Net. Around 35 mins in the last IMC for wording of when update might be. Something like, end of July , early summer, if that slips into early Aug. don't go blowing up BBs. I'm not going to give you hard numbers (I think referring to dates).

Sterling work, AS. Thanks for posting your research and estimates.

SOH has been guilty in the past of playing around with descriptors in the commentary accompanying results. Variously using eg revenue/sales/orders to show things a positive light.

I must admit I overlooked the term used in the income statement this time, assuming gross revenue was revenue.

Was this one I think.

https://www.google.co.uk/shopping/product/13795809863665206756

There was a probiotic cleaner advertised on either ITV or Channel 4. Was watching on catch up. But did catch my eye vis SBTX.

Is it or isn't it?

I follow this share closely but am not invested. Temporarily held a small number a few year's ago.

Didn't think I would say this but "respect" to C News who was IMO too positive, but has now recognised he was wrong, either by being misled or guilty of confirmation bias.

This, again IMO is a company with potentially great ideas and products. But doesn't control costs. Though TBF, it needs loads of money for capex. And has to be beholden to large partners, often unnamed.

And Chancellor wants more people to invest in shares on AIM. It is far too risky for most PIs as I have learnt the hard way. Be happy to protect your capital and get modest interest rates.

Probably not but read on

https://www.bbc.co.uk/news/articles/czxe59zl8qzo

Think the rise was a for a few days. But you may be right. Perhaps up a bit more before before usual AIm drift and fall back. Although LT it's a hold, wouldn't be buying today. The S/t profit has gone.

And today's

· Gross revenue +33% to £1.34m (H1 2024: £1.01m)

· Gross profit +33% to £748,000 (H1 2024: £564,000)

· EBITDA loss significantly reduced by 59% to £110,000 (H1 2024: £268,000 loss)

· Strong cash balance of £1.3m (H1 2024: £865,000)

· Current order book at record level which augurs well for H2

Well done!!!

For info, this is what we got at this time last year:

. Turnover: £1.005m (2023: £0.522m)

· Gross profit %: >50%; (2023: 48%)

· EBITDA loss £0.275m (2023: £0.512m)

Got to be a buy at these prices. Even if for a quick profit after update.

I hope this is not another example of where one revenue stream comes on line and another one gets turned off.

Lord, as AS points out, it seems to be for Dr M overall. I mistakenly took it to be the product which was the one with brown packaging.

AS thanks.

This is a link to Amazon India for Lightlife. For one of the offerings says "top brand". 89% positive rating from 10k + customers. Is this good or not?

https://www.amazon.in/s?k=lightlife+by+dr+morepen+weight+loss&crid=JPT6RGV2N0NA&sprefix=lightlife%2Caps%2C91&ref=nb_sb_ss_mvt-t11-ranker_1_9

Letit , thanks for note that Q&A available. Seems to address some issues, though perhaps still a bit vague. Only had a quick look. For those who feel their question was avoided, are there some/any glaring omissions.

In general, there really needs to be more time for Q&A. And ideally a facility to follow up. This would help where questioner feels question has been misunderstood or where probing would help.

This work is still ongoing (no don't yawn). The following buried in the FY report could be important.

"While OptiBiotix's commercial focus has been on overweight individuals, recent work with dieticians at a speciality London obesity clinic has indicated that SlimBiome® may have potential as an adjunct to treatment with Ozempic/Wegovy.

Reports suggest that patients taking anti-obesity drugs often experience a decreasing effect over time, despite increasing their dose. To counter this, a small number of patients were given SlimBiome® with patients reporting an enhanced appetite suppressant effect. Work is ongoing to explore whether SlimBiome® combined with Ozempic may help to reduce drug dosage (and cost) and enhance or prolong the appetite suppressant effect of these anti-obesity drugs."

Boots cancelled it. Can't remember reason.